Inventiva SA IVA
EURONEXT · France · Health Technology
€3.05-0.25 (-7.59%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
European equities traded in the US as American depositary receipts were lower on Tuesday morning, de
Lanifibranor Phase III results expected Q4 2026, potential FDA submission H1 2027.
Inventiva SA (IVEVF) reported EUR233.9 million in cash and reaffirmed Q4 2026 top-line NATIV3 data for its MASH therapy lanifibranor, keeping a potential NDA submission on track for H1 2027.
Inventiva (NASDAQ:IVA) said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after the last patient completed the study’s 72-week visit earlier this month. Chie
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.